📊 RCUS Key Takeaways
Is Arcus Biosciences, Inc. (RCUS) a Good Investment?
Arcus Biosciences shows exceptional revenue growth (648.5% YoY) suggesting recent product commercialization, but is burning cash at unsustainable rates (-$138M operating loss on only $17M revenue) with approximately 1.5-2 years of cash runway remaining. While the balance sheet is currently solid with strong liquidity and modest debt, the company requires dramatic operating margin improvement or continued capital raises to survive long-term.
Arcus Biosciences, Inc. Key Strengths (RCUS)
- Exceptional revenue growth of 648.5% YoY indicating successful product launch or market penetration
- Strong liquidity position (4.04x current ratio) and $201M cash reserves provide operational runway
- Conservative leverage (0.19x debt/equity ratio) maintains financial flexibility for potential capital raises
RCUS Stock Risks: Arcus Biosciences, Inc. Investment Risks
- Unsustainable operating burn rate of -$138M annually on only $17M revenue creates severe near-term cash depletion risk
- At current burn rates, cash runway extends only 12-18 months before depletion or required capital raise
- Deeply negative margins (-788.2% operating margin) indicate company has not yet achieved viable unit economics despite growth
- Pharmaceutical sector execution risk: future viability depends entirely on pipeline success, regulatory approvals, and ability to scale profitably
Key Metrics to Watch
- Quarterly revenue growth trajectory and gross margins (actual profitability at product level)
- Operating expense burn rate reduction and path to profitability timeline
- Remaining cash runway and potential need for capital raise
- Clinical pipeline progress, regulatory milestones, and product commercialization expansion
Arcus Biosciences, Inc. (RCUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.04x current ratio provides a solid financial cushion.
RCUS Profit Margin, ROE & Profitability Analysis
RCUS vs Healthcare Sector: How Arcus Biosciences, Inc. Compares
How Arcus Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arcus Biosciences, Inc. Stock Overvalued? RCUS Valuation Analysis 2026
Based on fundamental analysis, Arcus Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arcus Biosciences, Inc. Balance Sheet: RCUS Debt, Cash & Liquidity
RCUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arcus Biosciences, Inc.'s revenue has declined by 87% over the 5-year period, indicating business contraction. The most recent EPS of $-4.15 indicates the company is currently unprofitable.
RCUS Revenue Growth, EPS Growth & YoY Performance
RCUS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.0M | -$112.0M | $-1.02 |
| Q3 2025 | $6.0M | N/A | $-1.00 |
| Q2 2025 | $8.0M | N/A | $0.00 |
| Q1 2025 | $8.0M | -$4.0M | $-0.05 |
| Q3 2024 | $32.0M | -$4.0M | $-0.94 |
| Q2 2024 | $29.0M | -$4.0M | $-1.02 |
| Q1 2024 | $25.0M | -$4.0M | $-0.05 |
| Q3 2023 | $32.0M | -$65.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arcus Biosciences, Inc. Dividends, Buybacks & Capital Allocation
RCUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arcus Biosciences, Inc. (CIK: 0001724521)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RCUS
What is the AI rating for RCUS?
Arcus Biosciences, Inc. (RCUS) has an AI grade of C with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RCUS's key strengths?
Claude: Exceptional revenue growth of 648.5% YoY indicating successful product launch or market penetration. Strong liquidity position (4.04x current ratio) and $201M cash reserves provide operational runway.
What are the risks of investing in RCUS?
Claude: Unsustainable operating burn rate of -$138M annually on only $17M revenue creates severe near-term cash depletion risk. At current burn rates, cash runway extends only 12-18 months before depletion or required capital raise.
What is RCUS's revenue and growth?
Arcus Biosciences, Inc. reported revenue of $17.0M.
Does RCUS pay dividends?
Arcus Biosciences, Inc. does not currently pay dividends.
Where can I find RCUS SEC filings?
Official SEC filings for Arcus Biosciences, Inc. (CIK: 0001724521) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RCUS's EPS?
Arcus Biosciences, Inc. has a diluted EPS of $-1.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RCUS's fundamental grade?
Based on our AI fundamental analysis in May 2026, Arcus Biosciences, Inc. has a C grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RCUS stock overvalued or undervalued?
Valuation metrics for RCUS: ROE of -24.4% (sector avg: 15%), net margin of -752.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RCUS's AI grade for 2026?
Our dual AI analysis gives Arcus Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RCUS's free cash flow?
Arcus Biosciences, Inc.'s operating cash flow is $-138.0M, with capital expenditures of $0.0. FCF margin is -811.8%.
How does RCUS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -752.9% (avg: 12%), ROE -24.4% (avg: 15%), current ratio 4.04 (avg: 2).